Rejected at 3:55 p.m. Aug, 17, 2024 ] by Ahmed7
Author: jja004
Related Note: 1505668551919
Rationale for change

This update changes the format to align with new Anking OS1/2 formating. It creates 2 cards instead of 3.

It now includes 2 additional tick-borne diseases (anaplasmosis, erlichiosis) whose preferred treatment for uncomplicated cases are tetracyclines (doxycycline). They were previously listed only in the extra field.

Amboss indicates that for all 5 organisms, doxycycline is their preferred treatment for uncomplicated disease.

Amboss indicates that the only indicated treatments for anaplasmosis and erlichiosis is doxycycline. There are other treatments for both borrelia and francisella.

The original card did not include anaplasmosis or erlichiosis in the cloze deletions despite tetracycline having coverage in these tick-borne disease and being the preferred treatment. The information was found in the pink text, but the lack of inclusion in the clozes places less importance on them despite their only treatment being a tetracycline.


Source: AMBOSS - https://next.amboss.com/us/article/P70WNh?q=tetracyclines#Qt1uWi0

Rejection reason

the original card is already poor and the new one will make it more memorization heavy. sketchy is sufficient for this and the fact that most of these zoonotic disease are treated with tetracyclines.

You can add this yourself by right-clicking on the card -> go to AnkiHub protect fields -> select the field you want to protect -> add it yourself and it won't be overwritten

Text Text
Extra Extra
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Sketchy
Sketchy 2
Empty field
Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize
Empty field
Physeo
Bootcamp
OME
Additional Resources
Empty field
One by one
Empty field
#AK_Step1_v12::#Physeo::^physeo_image_update #AK_Step1_v12::#OME::Clinical::Internal_Medicine::Infectious_Disease #AK_Step1_v12::!FLAG_THESE_CARDS::Potential_duplicates #AK_Step2_v12::#B&B::08_Infectious_Disease::01_Antibiotics::03_Protein_Synthesis_Inhibitors #AK_Step1_v12::#Bootcamp::Microbiology::16_Atypical_Bacteria::06_Ehrlichia_and_Anaplasma #AK_Step1_v12::#Bootcamp::Microbiology::36_Antibiotics::13_Tetracyclines_and_Derivatives #AK_Step1_v12::#SketchyMicro::01_Bacteria::09_Spirochetes::01_Borrelia_burgdorferi #AK_Step1_v12::#Bootcamp::Microbiology::14_Gram_Negative_Coccobacilli::03_Additional_Pathogens #AK_Step1_v12::#Physeo::09_Pharm::05_Antibiotics::11_Tetracyclines #AK_Other::#AK_Original_Decks::Step_1::Lolnotacop::Drugs #AK_Step1_v12::#Low/HighYield::1-HighYield #AK_Step1_v12::#SketchyMicro::01_Bacteria::07_Gram_(-)_Bacilli_-_Zoonotics::05_Anaplasma_phagocytophilum,_Ehrlichia_chaffeensis #AK_Step1_v12::#B&B::14_Infectious_Disease::02_Bacteria::07_Zoonotic_Infections #AK_Step1_v12::#Physeo::06_Micro::02_Bacteria::52_Ehrlichia_&_Anaplasma #AK_Step1_v12::#FirstAid::03_Microbiology::07_Antimicrobials::13_Tetracyclines #AK_Step1_v12::#B&B::14_Infectious_Disease::03_Antibiotics::04_Protein_Synthesis_Inhibitors::Extra #AK_Step1_v12::!FLAG_THESE_CARDS::PharmExtras_(topic_covered_by_micro) #AK_Step1_v12::#SketchyPharm::07_Antimicrobials::02_Inhibitors_of_Bacterial_Protein_Synthesis::01_Tetracyclines